Get Your Personalized Supplement StackSupplement Stack Quiz

Hedyotis

Q: Is Hedyotis diffusa effective for cancer?

Preclinical and limited clinical evidence suggest anti-cancer potential, particularly as an adjunct therapy, by inhibiting cancer cell proliferation and modulating immune responses. However, more rigorous clinical trials are needed to confirm these effects.

Q: Is it safe to use with chemotherapy?

Preliminary animal data indicate no significant pharmacokinetic interaction with sorafenib, suggesting potential compatibility. However, clinical safety data in humans are limited, so caution and medical supervision are advised.

Q: How long does it take to see effects?

In clinical studies, immune modulation, such as an increase in CD3+ T-cell levels, has been observed within weeks when Hedyotis-containing herbal formulas were used as an adjunct to conventional therapy.

Q: Are there standardized extracts?

Currently, there is no widely accepted standardization for Hedyotis diffusa extracts. The active components are known to include flavonoids and polysaccharides, but specific standardized preparations are not broadly available.

Also known as: Hedyotis, Oldenlandia diffusa, snake-needle grass, spreading hedyotis, Hedyotis diffusa Willd

Overview

Hedyotis diffusa Willd is a herbaceous plant widely utilized in traditional East Asian medicine, particularly Traditional Chinese Medicine (TCM). It is recognized for its purported anti-inflammatory, antitumor, and immune-modulating properties. This plant is native to Asia and is harvested for its medicinal components. Traditionally, it has been employed as an adjunctive treatment for various cancers, to support the immune system, and to manage inflammatory conditions such as rheumatoid arthritis. Its therapeutic effects are attributed to a rich profile of bioactive compounds, including flavonoids, polysaccharides, and iridoids. Research indicates its ability to induce anti-proliferative effects on cancer cells and modulate immune markers. While several preclinical studies and some clinical trials support its traditional uses, the overall research maturity is moderate, with a need for more high-quality randomized controlled trials and comprehensive meta-analyses.

Benefits

Hedyotis diffusa exhibits several evidence-based benefits, primarily in its antitumor and immune-modulating activities. Preclinical studies demonstrate significant antitumor activity, with extracts and flavonoids inhibiting the proliferation of various cancer cell lines, including hepatocellular carcinoma and kidney cancer, at IC50 values ranging from approximately 3–24 μg/ml. This suggests a direct cytotoxic effect on cancer cells. In terms of immune modulation, a meta-analysis of randomized controlled trials in non-small cell lung cancer (NSCLC) patients showed a statistically significant improvement in CD3+ T-cell levels (mean difference 10.60, 95% CI [7.22, 13.98], p < 0.001) when Hedyotis-containing herbal formulas were combined with chemotherapy. This indicates its potential to enhance immune responses in cancer patients. Additionally, in vitro studies suggest anti-inflammatory effects through the inhibition of the PI3K/AKT pathway in fibroblast-like synoviocytes, which is relevant to rheumatoid arthritis. While immune marker improvement is significant, clinical outcome data such as survival rates or tumor regression are still limited. The benefits appear most relevant for cancer patients, particularly those with NSCLC and hepatocellular carcinoma, and potentially for inflammatory conditions.

How it works

Hedyotis diffusa exerts its therapeutic effects through several biological pathways. A primary mechanism involves the induction of endoplasmic reticulum stress, which subsequently leads to apoptosis (programmed cell death) in cancer cells. This contributes to its observed anti-proliferative effects. Furthermore, Hedyotis diffusa has been shown to inhibit the PI3K/AKT signaling pathway. This pathway is crucial for cell survival, proliferation, and inflammation, so its inhibition can reduce cancer cell growth and inflammatory responses. The plant's compounds interact with the immune system by modulating immune cell activity, specifically increasing T-cell markers like CD3+, thereby enhancing immune function. It also suppresses tumor cell proliferation and reduces the activity of inflammatory fibroblasts. Key molecular targets include AKT phosphorylation and cell cycle regulators such as Ki67, which are involved in cell survival and proliferation.

Side effects

The overall safety profile of Hedyotis diffusa is generally considered favorable, particularly based on its extensive traditional use and findings from animal studies. However, comprehensive clinical safety data, especially from large-scale, high-quality clinical trials, are limited. Consequently, common, uncommon, or rare side effects are not well-documented in a clinical context. Traditional use suggests a low incidence of adverse effects. Regarding drug interactions, a pharmacokinetic study in rats indicated no significant interaction with sorafenib, a common chemotherapy drug, suggesting it might be safely co-administered with certain medications. However, this finding is from an animal model and requires human validation. Contraindications are not clearly established, but caution is advised when Hedyotis diffusa is used in conjunction with chemotherapy due to the limited clinical data. Safety in special populations such as pregnant women, children, or individuals with specific medical conditions has not been established, and therefore, its use in these groups should be approached with caution. Cancer patients undergoing chemotherapy represent a specific population where more rigorous safety data are needed.

Dosage

There is no standardized minimum effective dose or optimal dosage range for Hedyotis diffusa, as clinical studies often utilize herbal formulas containing the plant rather than isolated doses. Preclinical studies employ variable concentrations, making direct translation to human dosing challenging. The maximum safe dose has not been established due to the absence of dose-ranging clinical trials. In clinical settings, Hedyotis diffusa is typically used as an adjunct to chemotherapy over several weeks. Different forms of the plant, including extracts, total flavonoids, and polysaccharide fractions, have been studied, but whole herb preparations are common in traditional formulas. There are no specific timing considerations beyond its use as an adjunctive therapy. Pharmacokinetic studies in animal models suggest no significant impact on the absorption or metabolism of certain drugs like sorafenib, indicating potential compatibility. No specific cofactors are identified as being required for its efficacy.

FAQs

Is Hedyotis diffusa effective for cancer?

Preclinical and limited clinical evidence suggest anti-cancer potential, particularly as an adjunct therapy, by inhibiting cancer cell proliferation and modulating immune responses. However, more rigorous clinical trials are needed to confirm these effects.

Is it safe to use with chemotherapy?

Preliminary animal data indicate no significant pharmacokinetic interaction with sorafenib, suggesting potential compatibility. However, clinical safety data in humans are limited, so caution and medical supervision are advised.

How long does it take to see effects?

In clinical studies, immune modulation, such as an increase in CD3+ T-cell levels, has been observed within weeks when Hedyotis-containing herbal formulas were used as an adjunct to conventional therapy.

Are there standardized extracts?

Currently, there is no widely accepted standardization for Hedyotis diffusa extracts. The active components are known to include flavonoids and polysaccharides, but specific standardized preparations are not broadly available.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC11483700/ – This systematic review and meta-analysis of 5 RCTs involving 610 NSCLC patients found a significant increase in CD3+ immune markers when herbal medicine (including Hedyotis) was used as an adjunct to chemotherapy. The study suggests immune-modulating benefits but notes limitations due to heterogeneous interventions and a small number of RCTs.
https://pubs.acs.org/doi/10.1021/acsomega.0c05461 – This in vitro study investigated the effects of Hedyotis diffusa total flavonoids on hepatocellular carcinoma cell lines (HepG2, Hep3B, HCCLM3). It demonstrated that the flavonoids inhibited cancer cell proliferation with IC50 values ranging from approximately 3-24 μg/ml, providing preclinical evidence for its anti-proliferative effects.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1019670/full – This study combined network pharmacology with in vitro experiments on MH7A fibroblast-like synoviocytes. It revealed that Hedyotis diffusa inhibited the PI3K/AKT pathway, leading to reduced cell proliferation, offering mechanistic insight into its potential anti-inflammatory effects relevant to rheumatoid arthritis.
https://www.nature.com/articles/s41598-022-25579-3 – This pharmacokinetic study in rats investigated the interaction between Hedyotis diffusa extract and sorafenib. It found no significant alteration in sorafenib pharmacokinetics after 5 days of Hedyotis pretreatment, suggesting potential safety for co-administration in an animal model.